Outlook Therapeutics, Inc. (OTLK)
Last updated: 2026-10-24 23:13:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Outlook Therapeutics, Inc. (OTLK) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.52, with a market capitalization of $137.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.16 to $2.54. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$137.18M | |
$0.56 | |
$219.20 | |
$0.16 | |
$0.56 | |
3.03M | |
11.34M | |
-- | |
$2.54 | |
$0.16 | |
-- | |
-- |
Outlook Therapeutics, Inc. (OTLK) Latest Closing Stock Price
Outlook Therapeutics, Inc. (OTLK) last closed at $0.56 as of 2026-10-23 23:49:00, unchanged from the previous close of $0.56.
During the latest regular trading session, OTLK traded between $0.16 and $219.20, with a volume of 3.03M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Outlook Therapeutics, Inc. (OTLK) 7-Day Stock Price Change
Over the past seven days, Outlook Therapeutics, Inc. (OTLK) moved from $0.50 to $0.52, representing a gain of 4.40% ($0.02).
The stock traded between $0.44 and $0.60 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 3.55 million shares, down versus the previous seven-day period, indicating lower trading activity.
OTLK 52-Week Price Position
Position in Range: 15.2%
OTLK is currently trading at $0.52, placing it 15.2% of the way from its 52-week low of $0.16 to its 52-week high of $2.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Outlook Therapeutics, Inc. (OTLK)?
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Outlook Therapeutics, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Outlook Therapeutics, Inc. (OTLK) Stock on MEXC
Eligible investors can buy real shares of Outlook Therapeutics, Inc. (OTLK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Outlook Therapeutics, Inc. (OTLK) stock price today?
2.Is OTLK stock going up or down today?
3.What is OTLK pre-market price?
4.What is OTLK after-hours price?
5.Is OTLK stock trading now?
6.Where does OTLK sit relative to its 52-week high and low?
7.What sector is Outlook Therapeutics, Inc. in?
8.What is Outlook Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is OTLK valued in terms of P/E ratio and EPS?
10.Does Outlook Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
OTLK Stock Calculator
Estimate the value between OTLK shares and USD.
OTLK Shares to USD
1.00 OTLK shares = 0.522 USD
Calculations are estimates based on the latest available price and are for reference only.


